Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
NCT ID: NCT00535665
Last Updated: 2007-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
402 participants
INTERVENTIONAL
2007-09-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Total 400 volunteers aged from 18 to 60 years old are to be enrolled with 100 subjects in each group. The eligible volunteers will receive two doses vaccine of 5μg，10μg or 15μg haemagglutinin antigen. The schedule is day 0,14 or day 0,28. The subjects will donate their blood samples for the detection of HI antibody and microneutralization antibody. Local and systematic adverse reactions will be recorded during the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1: 10 ug, 14 days
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 14 days apart: 5 microgram per dose
2: 5 ug, 28 days
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 28 days apart: 5 microgram per dose
3: 10 ug, 28 days
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 28 days apart: 10 microgram per dose
4: 15 ug, 28days
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 28 days apart: 15 microgram per dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 14 days apart: 5 microgram per dose
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 28 days apart: 5 microgram per dose
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 28 days apart: 10 microgram per dose
pandemic influenza vaccine (H5N1 strain NIBRG-14)
two-dose regimen with 28 days apart: 15 microgram per dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to show legal identity card for the sake of recruitment
* Be able to understand and sign the informed consent.
Exclusion Criteria
* Any history of allergic reactions was allergic to any component of the vaccine, such as eggs or ovalbumin;
* Any history of severe adverse reactions to vaccines, such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
* Autoimmune disease or immunodeficiency
* Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
* Diabetes mellitus (type I or II), with the exception of gestational diabetes
* History of thyroidectomy or thyroid disease that required medication within the past 12 months
* Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
* Hypertension that was not well controlled by medication or is more than 145/95 mmHg at enrollment
* Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
* Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
* Seizure disorder other than:
1. Febrile seizures under the age of two years old,
2. Seizures secondary to alcohol withdrawal more than 3 years ago, or
3. A singular seizure not requiring treatment within the last 3 years
* Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
* Guillain-Barre Syndrome
* Women subjects with positive urinary pregnancy test
* Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
* History of any blood products administration within 3 months before the dosing
* Administration of any other investigational research agents within 30 days before the dosing
* Administration of any live attenuated vaccine within 30 days before the dosing
* Administration of subunit or inactivated vaccines, e.g. pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
* Be receiving anti-TB prophylaxis or therapy currently
* Axillary temperature \>37.0 centigrade at the time of dosing
* Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment
* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centers for Disease Control and Prevention, China
OTHER_GOV
Sinovac Biotech Co., Ltd
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiang Wu
Role: PRINCIPAL_INVESTIGATOR
Beijing Centers for Diseases Control and Prevention
References
Explore related publications, articles, or registry entries linked to this study.
Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO-PanFlu-2001
Identifier Type: -
Identifier Source: org_study_id